Open AccessMARCKS promotes invasion and is associated with biochemical recurrence in prostate cancer
Author(s) -
Emma Dorris,
Amanda O’Neill,
Karen Hanrahan,
Ann Treacy,
R. William G. Watson
Publication year - 2017
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.18894
Subject(s) - marcks , prostate cancer , cancer research , medicine , gene knockdown , metastasis , tissue microarray , cancer , prostate , cell migration , viability assay , pathology , apoptosis , oncology , cell , biology , signal transduction , microbiology and biotechnology , protein kinase c , biochemistry , genetics
Overtreatment of low-grade prostate cancer is a recognised problem for clinicians and patients. However, under-treatment runs the risk of missing the opportunity for cure in those who could benefit. Identification of new biomarkers of disease progression, including metastases, is required to better stratify and appropriately treat these patients. The ability to predict if prostate cancer will recur is an important clinical question that would impact treatment options for patients. Studies in other cancers have associated MARCKS with metastasis.